Login Register Cart 0
Research Article

无细胞血浆DNA对转移性和非转移性前列腺癌的影响

卷 22, 期 1, 2022

发表于: 25 February, 2021

页: [67 - 73] 页: 7

弟呕挨: 10.2174/1566524021666210225101358

摘要

导言:细胞游离DNA (cfDNA)增加在许多疾病中被观察到，如癌症、心肌梗死和自身免疫性疾病。它有能力改变受体细胞的表型，触发相关的恶性转化事件。目的:我们的研究旨在评估使用细胞游离血浆DNA诊断转移性和非转移性前列腺癌。方法:本研究纳入180名受试者，分为四组:I组(GI)包括50例完全健康者作为对照组，II组(GII)包括40例前列腺炎患者，III组(GIII)包括40例良性前列腺增生(BPH)患者，IV组(GIV)包括50例术前前列腺癌(PC)患者。采用实时荧光定量PCR (real-time PCR)检测各组血浆循环细胞游离DNA水平，并测定总PSA (tPSA)和游离总PSA% (f/tPSA%)。结果:我们的研究发现前列腺癌患者tPSA水平显著升高，而f/t PSA水平显著降低。cfDNA水平在前列腺癌组中分别为399.9�88.6ng/ul (p<0.01)、14.7�2.4 ng/ul (p<0.01)、26.6�45.6 ng/ul (p<0.01)，差异有统计学意义(p<0.01)。结论:cfDNA产率在转移组和非转移组之间有统计学差异(P=0.03)，转移组更高。

关键词: 循环细胞游离DNA，前列腺癌，良性前列腺增生，前列腺炎，总PSA，游离PSA。

« Previous Next »
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Siege L, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016; 66: 7-30.
[3]
Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010; 7(9): 487-93.
[http://dx.doi.org/10.1038/nrurol.2010.120] [PMID: 20818326]
[4]
Porcaro AB, Migliorini F, Romano M, et al. Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients. Int Urol Nephrol 2010; 42(3): 673-81.
[http://dx.doi.org/10.1007/s11255-009-9669-z] [PMID: 19902378]
[5]
Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009; 101(11): 1833-8.
[http://dx.doi.org/10.1038/sj.bjc.6605422] [PMID: 19904272]
[6]
Mouliere F, Robert B, Arnau Peyrotte E, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011; 6(9)e23418
[http://dx.doi.org/10.1371/journal.pone.0023418] [PMID: 21909401]
[7]
Casadio V, Salvi S, Martignano F, Gunelli R, Ravaioli S, Calistri D. Cell-free DNA integrity analysis in urine samples. J Vis Exp 2017; 5(119)
[http://dx.doi.org/10.3791/55049] [PMID: 28117781]
[8]
Stroun M, Anker P. Circulating DNA in higher organisms cancer detection brings back to life an ignored phenomenon. Cell Mol Biol 2005; 51(8): 767-74.
[PMID: 16359626]
[9]
Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22(20): 4157-64.
[http://dx.doi.org/10.1200/JCO.2004.11.123] [PMID: 15483026]
[10]
McGuire AL, Urosevic N, Chan DT, Dogra G, Inglis TJ. The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels. PPAR 2014; p. 643189.
[11]
Batth IS, Mitra A, Manier S, et al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol 2017; 28(3): 468-77.
[http://dx.doi.org/10.1093/annonc/mdw619] [PMID: 27998963]
[12]
Duffy MJ. PSA in screening for prostate cancer: more good than harm or more harm than good? Adv Clin Chem 2014; 66: 1-23.
[http://dx.doi.org/10.1016/B978-0-12-801401-1.00001-3] [PMID: 25344984]
[13]
Lu JL, Liang ZY. Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns. Chronic Dis Transl Med 2016; 2(4): 223-30.
[http://dx.doi.org/10.1016/j.cdtm.2016.12.001] [PMID: 29063046]
[14]
Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010; 10(2): 142-65.
[http://dx.doi.org/10.2174/156652410790963295] [PMID: 20196731]
[15]
Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56(2): 255-60.
[http://dx.doi.org/10.1016/S0090-4295(00)00637-3] [PMID: 10925089]
[16]
Omar J, Jaafar Z, Abdullah MR. A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening. Malays J Med Sci 2009; 16(1): 44-7.
[PMID: 22589648]
[17]
Li J, Gregory SG, Garcia-Blanco MA, Armstrong AJ. Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Crit Rev Clin Lab Sci 2015; 52(4): 191-210.
[http://dx.doi.org/10.3109/10408363.2015.1023430] [PMID: 26079252]
[18]
Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin Chem 2010; 56(8): 1279-86.
[http://dx.doi.org/10.1373/clinchem.2010.144188] [PMID: 20558635]
[19]
Perkins G, Yap TA, Pope L, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012; 7(11)e47020
[http://dx.doi.org/10.1371/journal.pone.0047020] [PMID: 23144797]
[20]
Elnadry M, Alkelany Y F, Amin M. Level of circulating cell-free DNA in the serum of Egyptian patients as a biomarker for diagnosis and prognostic prediction of colorectal cancerEjpmr 2017; 4(5)
[21]
Seyedolmohadessin SM, Akbari MT, Nourmohammadi Z, Basiri A, Pourmand G. Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening. Iran Biomed J 2018; 22(5): 331-7.
[http://dx.doi.org/10.29252/ibj.22.5.331] [PMID: 29475366]
[22]
Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci 2004; 1022: 76-80.
[http://dx.doi.org/10.1196/annals.1318.013] [PMID: 15251943]
[23]
Gordian E, Ramachandran K, Reis IM, Manoharan M, Soloway MS, Singal R. Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev 2010; 19(8): 1984-91.
[http://dx.doi.org/10.1158/1055-9965.EPI-10-0287] [PMID: 20647404]
[24]
Karima M. Sweify, AmalFawzy, Hany M. El-Fayoumy, Nagwa Nofal: Evaluation of cell free circulating plasma DNA in prostate cancer. J Sci Res Sci 2018; 34(1): 108-22.
[http://dx.doi.org/10.21608/jsrs.2018.12760]
[25]
Jung K, Stephan C, Lewandowski M, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett 2004; 205(2): 173-80.
[http://dx.doi.org/10.1016/j.canlet.2003.11.023] [PMID: 15036649]

Rights & Permissions Print Cite
Article Metrics
18
3
© 2025 Bentham Science Publishers | Privacy Policy